AU2022323324A1 - Leptospiral virulence modulating proteins and uses thereof - Google Patents

Leptospiral virulence modulating proteins and uses thereof Download PDF

Info

Publication number
AU2022323324A1
AU2022323324A1 AU2022323324A AU2022323324A AU2022323324A1 AU 2022323324 A1 AU2022323324 A1 AU 2022323324A1 AU 2022323324 A AU2022323324 A AU 2022323324A AU 2022323324 A AU2022323324 A AU 2022323324A AU 2022323324 A1 AU2022323324 A1 AU 2022323324A1
Authority
AU
Australia
Prior art keywords
seq
lic
lmanv2
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022323324A
Other languages
English (en)
Inventor
Joseph VINETZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2022323324A1 publication Critical patent/AU2022323324A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022323324A 2021-08-06 2022-08-05 Leptospiral virulence modulating proteins and uses thereof Pending AU2022323324A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163230244P 2021-08-06 2021-08-06
US63/230,244 2021-08-06
PCT/US2022/074601 WO2023015290A1 (en) 2021-08-06 2022-08-05 Leptospiral virulence modulating proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU2022323324A1 true AU2022323324A1 (en) 2024-03-21

Family

ID=85156339

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022323324A Pending AU2022323324A1 (en) 2021-08-06 2022-08-05 Leptospiral virulence modulating proteins and uses thereof

Country Status (6)

Country Link
US (1) US20240277823A1 (enExample)
EP (1) EP4380608A4 (enExample)
JP (1) JP2024529044A (enExample)
CN (1) CN117979992A (enExample)
AU (1) AU2022323324A1 (enExample)
WO (1) WO2023015290A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025208019A1 (en) * 2024-03-29 2025-10-02 Yale University Leptospiral virulence modulating protein epitopes and uses thereof
WO2026006400A2 (en) * 2024-06-25 2026-01-02 Luna Bioscience, Inc. A virulence modifying protein-based recombinant vaccine and rapid diagnostic assay for leptospira

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700263A1 (ru) * 2004-07-01 2007-06-29 Кебенхавнс Университет Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции
AU2016219787B2 (en) * 2015-02-20 2019-05-30 Calixar Leptospira immunoprotective proteins and methods of identification and use thereof
EP4100050A4 (en) * 2020-02-07 2024-07-10 Yale University Leptospiral proteins and uses thereof

Also Published As

Publication number Publication date
WO2023015290A1 (en) 2023-02-09
CN117979992A (zh) 2024-05-03
EP4380608A4 (en) 2026-04-15
EP4380608A1 (en) 2024-06-12
US20240277823A1 (en) 2024-08-22
JP2024529044A (ja) 2024-08-01

Similar Documents

Publication Publication Date Title
KR101748453B1 (ko) 폐렴구균(Ｓｔｒｅｐｔｏｃｏｃｃｕｓ Ｐｎｅｕｍｏｎｉａｅ)에 대항하는 백신과 조성물
JP6084631B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
US20090226469A1 (en) Shiga Toxoid Chimeric Proteins
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
JP6894237B2 (ja) 変異体ブドウ球菌抗原
CA2884918C (en) Salmonid alphavirus and uses thereof
US20240277823A1 (en) Leptospiral virulence modulating proteins and uses thereof
JP2015529677A (ja) ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド
JP2014527084A (ja) Ｈｙｒ１由来組成物およびそれを使用する処置方法
US12595287B2 (en) Leptospiral proteins and uses thereof
Mirali et al. A two-protein cocktail elicits a protective immune response against Acinetobacter baumannii in a murine infection model
Hsieh et al. Extended low-resolution structure of a Leptospira antigen offers high bactericidal antibody accessibility amenable to vaccine design
JP2019531100A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
Huang et al. Biochemical and immunological characterization of truncated fragments of the receptor-binding domains of C. difficile toxin A
US10646561B2 (en) Compositions and methods for using Salmonella typhi toxin to induce or enhance an immune response
JP2024512751A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓワクチン組成物
TW202528336A (zh) 蛋白質奈米結構疫苗
US20180153990A1 (en) Pca1 protein and methods of treating pneumocystis pneumonia infection
JP2021524485A (ja) パラ結核症のための免疫原性組成物
HK40106181A (en) Leptospiral virulence modulating proteins and uses thereof
US10335477B2 (en) Compositions and methods for diagnosing, preventing and treating Salmonella typhi and Salmonella paratyphi infection
JP2021505525A (ja) Ａ群レンサ球菌に対する免疫原性ペプチド
Badten et al. Evaluation of highly conserved Burkholderia pseudomallei outer membrane proteins as protective antigens against respiratory melioidosis
TW200530399A (en) Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2025208019A1 (en) Leptospiral virulence modulating protein epitopes and uses thereof